Loading organizations...
§ Public · Cambridge, MA, USA
Werewolf Therapeutics is a technology company.
Werewolf Therapeutics develops novel cancer immunotherapies, employing conditionally activated proinflammatory immune modulators. Utilizing proprietary PREDATOR® protein engineering, these therapeutics remain inert in healthy tissues, activating exclusively within the tumor microenvironment. This enables a targeted immune response against cancer, minimizing systemic side effects common in immuno-oncology.
Founded in 2017 by Dan Hicklin and Luke Evnin, Werewolf Therapeutics stemmed from the insight for localized immune activation. These experienced scientists conceived treatments that, like a 'werewolf,' stay dormant until specific tumor conditions trigger potent effects. This concept drives their strategy to overcome broad-acting immunotherapy limitations.
The company focuses on delivering transformative treatment options for cancer patients. Werewolf Therapeutics aims to bring effective, targeted immunotherapies to clinical practice, improving patient outcomes. They are committed to pioneering therapies that selectively unleash the body’s natural defenses at the disease site.
Werewolf Therapeutics has raised $128.0M across 2 funding rounds.
Werewolf Therapeutics has raised $128.0M in total across 2 funding rounds.
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated biologic therapies to stimulate the immune system against cancer and immune-mediated conditions.[1][2][3] It engineers INDUKINE™ and INDUCER™ molecules using its proprietary PREDATOR® platform, which remain inactive systemically but activate selectively in the tumor microenvironment to enhance efficacy and minimize toxicities of cytokines like IL-2, IL-12, and IFNα.[2][3][7] The company serves cancer patients with solid tumors, addressing unmet needs in immunotherapy by targeting limitations of conventional proinflammatory therapies.[1][2] Its lead candidates, WTX-124 (IL-2 INDUKINE™) and WTX-330 (IL-12 INDUKINE™), are in Phase 1/2 trials showing early promise, including a confirmed partial response in metastatic gall bladder cancer, with a cash runway into Q4 2026 supporting pipeline advancement.[3][4][7]
Werewolf Therapeutics emerged from innovative science analogized to a werewolf: molecules that lie dormant systemically but transform into potent predators in tumors.[2] Founded as an oncology biotherapeutics company, it leverages the PREDATOR® protein engineering platform invented by its experienced scientists to create next-generation cancer treatments.[2][3][6] Key leadership includes Dan Hicklin, PhD, President and CEO, who has guided the company through clinical development, emphasizing tumor-activated immunotherapies.[3] Early traction stems from advancing WTX-124 into trials, demonstrating tolerability and responses in refractory cancers, with pivotal updates as of December 2025.[3]
Werewolf rides the immuno-oncology wave, where immunotherapy advances like checkpoint inhibitors face challenges from off-target toxicities and limited responses in "cold" tumors.[2][3] Its conditional activation addresses historical cytokine failures (e.g., severe toxicity of recombinant IL-2/IL-12), aligning with market forces favoring targeted, systemically delivered therapies amid growing demand for safer options in refractory cancers.[1][2][4] Timing benefits from maturing T-cell engager tech and FDA pathways for accelerated approval, positioning Werewolf to influence the ecosystem by pioneering "precision immuno-oncology" for immunologically unresponsive indications.[1][3][4]
Werewolf's 2026 priorities center on WTX-124 data from over 100 patients (Q4 2025 updates), WTX-330 Phase 1b/2 enrollment (NCT06939283), and expanding INDUCER™/INDUKINE™ pipelines into new antigens like CDH6 and IFNα.[3][4][7] Trends like AI-driven protein engineering and combo regimens with checkpoints will shape progress, potentially evolving its influence toward leadership in tumor-selective immunomodulators if clinical momentum sustains.[3][4] This targeted immune "transformation" could redefine cancer care, fulfilling its mission to pioneer safer, potent therapies.[1][2]
Werewolf Therapeutics has raised $128.0M across 2 funding rounds. Most recently, it raised $72.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2021 | $72M Series B | Derek Dirocco | Adage Capital Management, Arkin BIO Ventures, Caas Capital Management, DC Investment Partners, Elise Wang, HBM Healthcare Investments, Longwood Fund, MPM Capital, Soleus Capital, Sphera Healthcare, Taiho Ventures, UPMC Enterprises | Announced |
| Nov 1, 2019 | $56M Series A | MPM Capital, Longwood Fund | Deerfield Management, Hercules Capital, Arkin BIO Ventures, DC Investment Partners, Taiho Ventures, UPMC Enterprises | Announced |
Werewolf Therapeutics has raised $128.0M in total across 2 funding rounds.
Werewolf Therapeutics's investors include Derek DiRocco, Adage Capital Management, Arkin Bio Ventures, CaaS Capital Management, DC Investment Partners, Elise Wang, HBM Healthcare Investments, Longwood Fund, MPM Capital, Soleus Capital, Sphera Healthcare, Taiho Ventures.